Sponsors (4)
The bill speeds patient access to cadaveric islet transplants and reduces provider regulatory burden, but does so by reducing traditional FDA oversight—raising meaningful safety, accountability, and potential public-cost risks.
Patients with type 1 diabetes could gain faster access to transplantable cadaveric islets because the bill removes or shortens FDA drug/biologic approval pathways, speeding treatment availability.
Hospitals and transplant centers will face fewer regulatory barriers and administrative steps to treat patients with cadaveric islets, potentially lowering administrative costs and reducing time-to-treatment.
HHS must report to Congress on implementation timelines and related matters, increasing transparency and giving policymakers visibility into how the regulatory changes are carried out.
Patients receiving cadaveric islet transplants may face higher safety and quality risks because removing standard FDA drug/biologic or HCT/P premarket review reduces established oversight before use.
If adverse events occur, patients may have fewer regulatory protections and less-clear pathways for recourse or consistent manufacturing oversight, complicating accountability and legal remedies.
Taxpayers and HHS could face new costs if the government needs to build alternate oversight frameworks or respond to safety incidents after removing FDA pathways.
Based on analysis of 2 sections of legislative text.
Adds human cadaveric islets to a Public Health Service Act exemption so they are not regulated as drugs, biological products, or HCT/Ps, and directs HHS/FDA to update rules and report to Congress.
Amends federal law to add "human cadaveric islets" to an exemption in the Public Health Service Act so they are not treated as drugs, biological products, or HCT/Ps under specific federal definitions. Directs the HHS Secretary (and FDA as applicable) to update implementing regulations within one year and to report regulatory progress to Congress within six months. The change creates a clearer regulatory pathway for islet material used in transplantation and research, potentially reducing regulatory barriers for transplant centers, researchers, and patients pursuing islet transplantation therapies. The legislation does not provide new funding.
Introduced March 19, 2026 by Ralph Norman · Last progress March 19, 2026